Financials
Financial year 2025
VA PHARMA from Binche, company number BE0508521312, closed financial year 2025 with a result of € 58,359 after tax. For that financial year VA PHARMA recorded a gross margin of € 161,071 and equity of € 409,268. Compared with financial year 2024, the result moved from € 78,462 to € 58,359. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 409,268
▲ 17% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 58,359
▼ 26% vs 2024
Profit after tax over the fiscal year.
€ 298,103
▲ 37% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 403,068.
People and assets in 2025
0.6
Average over the fiscal year, from the social balance sheet.
€ 33,384
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 908
▼ 33% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 253,474
▼ 16% vs 2024
€ 60,087 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 206,177
▲ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 28,304
▼ 44% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 192,829 | € 188,041 | € 194,976 | € 161,071 | ▼ 17% |
| Profit after taxes | € 64,181 | € 75,781 | € 78,462 | € 58,359 | ▼ 26% |
| Equity | € 196,665 | € 272,446 | € 350,908 | € 409,268 | ▲ 17% |
| Total debts | € 530,094 | € 644,324 | € 550,904 | € 488,974 | ▼ 11% |
| Cash | € 118,988 | € 294,096 | € 217,542 | € 298,103 | ▲ 37% |
| Land & buildings | € 194,091 | € 158,987 | € 4,822 | € 3,749 | ▼ 22% |
| Retained profit | € 190,465 | € 266,246 | € 344,708 | € 403,068 | ▲ 17% |
| Bank debt | € 408,850 | € 355,758 | € 303,022 | € 253,474 | ▼ 16% |
| Balance sheet total | € 726,759 | € 916,770 | € 901,813 | € 898,242 | |
| Employees (FTE) | - | 0.6 | 0.6 | 0.6 |
Key figures of VA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to VA PHARMA?
What happened at VA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 58,359 (▼ 26% vs 2024). filed late Source: NBB ↗
- New establishment in Binche. KBO
- FRANCOIS VANLAUTEM became a director. NBB
- MAUREEN ANDRE became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 64,181 profit in 2022 to € 58,359 profit in 2025.
Paid € 109,396 in corporate taxes since 2022.
Best year ever: 2024, with € 78,462 profit.
Management
Behind VA PHARMA are FRANCOIS VANLAUTEM and MAUREEN ANDRE. The same people are also behind VA IMMO.
Establishments
Establishment units
Physical locations of this company
Rue de Cent Pieds(BUV) 86
7133 Binche
Rue de Robiano(BIN) 66
7130 Binche
Active since 18 December 2012
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0508.521.312
- VAT number
- BE 0508.521.312
- Registered office
- Rue de Cent Pieds(BUV) 86, 7133 Binche
- Names & denominations
- VA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 December 2012
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten